Could a drug combo free liver transplant patients from daily anti-rejection pills?
NCT ID NCT06832189
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether switching from the standard anti-rejection drug tacrolimus to everolimus plus epoetin can safely allow liver transplant recipients to stop all immunosuppressants. Twenty stable adult patients who received a liver transplant 1–10 years ago will take part. The main goal is to see if this approach is safe and can lead to 'operational tolerance'—where the body accepts the new liver without needing lifelong medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern University Feinberg School of Medicine
RECRUITINGChicago, Illinois, 60611, United States
-
University of California San Francisco School of Medicine
RECRUITINGSan Francisco, California, 94143, United States
-
University of Pennsylvania Medical Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can personalized antibiotics outsmart resistant bacteria in liver transplants?
- Blood-Clotting showdown: which device best guides bleeding care in High-Risk patients?
- Could a daily pill shield transplant patients from a common virus?
- Which liver biopsy needle delivers the best tissue? a Head-to-Head comparison
- Transplant breakdown? new study checks organ fluid for hidden germs
- New study aims to catch transplant complications early with blood and urine tests